AMERICAN JOURNAL OF HEMATOLOGY/ONCOLOGY: Can combination therapy with Celebrex and Lipitor effectively treat patients with early-stage prostate cancer? A new study at The Cancer Institute of New Jersey (CINJ) will explore that question.
Recent studies have shown that celecoxib and atrovastatin individually have effects on blocking nuclear factor kappa B (NFkB), the protein complex that, in many cases, can cause tumor cells to grow. By combining the two drugs, researchers will attempt to prevent tumor cells from growing and make them more sensitive to cancer-killing drugs. READ MORE>
